Candel Therapeutics Joins H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

NEEDHAM, Mass., June 18, 2024 – Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a biopharmaceutical company at the clinical stage, is committed to creating multimodal biological immunotherapies to aid cancer patients. Today, the Company has announced that Paul Peter Tak, MD, PhD, FMedSci, who is serving as Candel’s President and CEO, will be a part of a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 3:00 p.m. ET.

The fireside chat will be broadcast live and can be accessed under the Investors section on Candel’s website. Additionally, the webcast will be available for replay for up to 90 days following the session.

Overview of Candel Therapeutics

Candel Therapeutics is focused on developing off-the-shelf multimodal biological immunotherapies designed to provoke a personalized, systemic anti-tumor immune response. The company has built two clinical-stage immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs.

Key Product Candidates

CAN-2409: This is the leading product from the adenovirus platform and is being tested in several clinical trials. These include phase 2 trials for non-small cell lung cancer (NSCLC) and borderline resectable pancreatic ductal adenocarcinoma, as well as both phase 2 and phase 3 trials for localized, non-metastatic prostate cancer. Candel recently shared promising overall survival data for CAN-2409 in pancreatic cancer and NSCLC. The product has received Fast Track Designation from the FDA for prostate cancer, pancreatic cancer, and NSCLC, along with Orphan Drug Designation for pancreatic cancer. Topline data for phase 2b and phase 3 trials in localized prostate cancer are anticipated in Q4 2024.

CAN-3110: This is the leading candidate from the HSV platform and is currently undergoing a phase 1b clinical trial for recurrent high-grade glioma (rHGG). Clinical activity and biomarker data were published in Nature in October 2023. CAN-3110 also received both Fast Track and Orphan Drug Designations from the FDA for recurrent high-grade glioma. Further clinical updates are expected in the second half of 2024.

enLIGHTEN™ Discovery Platform

Candel is leveraging its enLIGHTEN™ Discovery Platform, an HSV-based technology, to develop new viral immunotherapies for solid tumors. At the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting, the company revealed promising data for its first immunotherapy candidate, Alpha 201-macro-1, which targets the CD47/SIRP1α pathway and was tested in mouse models of breast and lung cancer. During the American Association for Cancer Research (AACR) Annual Meeting in April 2024, Candel presented preclinical data on its second immunotherapy candidate designed to induce tertiary lymphoid structures (TLS) as a novel approach for treating solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!